Anti-cyclic citrullinated peptide antibodies are usually considered severe when they exceed 5 RU/mL and normal when they are less than 5 RU/mL; anti-cyclic citrullinated peptide antibodies, also known as anti-CCP antibodies, can be present in rheumatoid arthritis, which can cause severe clinical symptoms. Anti-cyclic citrullinated peptide antibodies are specific antibodies for rheumatoid arthritis, and more than 5RU/mL can cause rheumatoid arthritis, which is mainly manifested by joint swelling, morning stiffness and pain, and in the late stage, there will be narrowing of the joint space and bone destruction, which will ultimately lead to deformation of the joints and even disability. In addition to the involvement of joint parts, it will also involve other organs in the body, mainly including the lungs and cardiovascular system, leading to pleural effusion, interstitial lung disease, coronary heart disease, myocarditis, cardiac valvulopathy and so on. With elevated anti-cyclic citrullinated peptide, it is recommended to consult a regular hospital for early and standardized treatment to reduce the adverse effects of the disease.